Evaluation of PDTC for Removing Ni(II) from Human Serum Transferrin in Vitro

Pyrrolidine dithiocarbamate (PDTC) can be an oral chelator with pKa= 3.300±0.002. It behaves as a bidentate ligand at serum pH. The effect of pH on Ni2+-Tf indicated that the maximum adsorption was at pH=7.4. The effective Ni-PDTC binding constant was determined (logk=11.1±0.1) for the 1:2 Ni(PDTC)2 complex using UV-vis spectra. The isosbestic point at 298 indicated that the complexation reaction was done directly (without side reaction). Removal of Ni from transferrin (Tf) was investigated by reverse titration of PDTC at 25°C and pH=7.4 using UV-vis spectra. PDTC is able to remove 25% of Ni from human serum transferrin.

Removal of cadmium by combining deferasirox and desferrioxamine chelators in rats

An investigation was conducted to evaluate the ability of two chelators, deferasirox and desferrioxamine (DFO), in removing cadmium from biological system. The potential efficiency of those chelators were investigated after cadmium administration for 60 days following two dose levels of 20 and 40 mg/kg body weight daily to male rats. However, abnormalities were observed in clinical signs after cadmium administration, such as yellowish discoloration of hair, flaccid and hypotonic muscles, irritability, weakness and loss of weight. The hypothesis that the two chelators might be more efficient as combined therapy than single therapy in removing metal ions from the body was considered. In this way, two known chelators, deferasirox and DFO were chosen and tested in the acute rat model. The chelation therapy results show that deferasirox and DFO are able ?to remove cadmium ions from the body, while iron concentration returned to the normal level and symptoms are decreased.

Cadmium transport in blood serum

The binding of Cd2+ to human serum transferrin in 0.1 M N-(2-hydroxyethyl) piperazine-N ′-2-ethanesulfonic acid and 5 mM sodium bicarbonate at pH 7.4 has been studied by difference ultraviolet spectrophotometry. The apparent association constants were found to be 2.61 × 105 M —1 and 8.51 × 104M— 1, respectively. These association constants are pH-dependent, reducing with both increasing and decreasing pH. The apparent pKa values were found to be 4.93 and 5.42. Competitive assays of binding of Cd2+ to transferrin in the presence of citrate and human serum albumin at molar ratios corresponding to those found in normal plasma showed that a considerable amount of Cd2+ was not bound to transferrin. The competitive binding assays indicate that ∼50% of Cd2+ is bound to transferrin, ∼37% to albumin and reminder to citrate. These results therefore suggest that, although transferrin at pH 7.4 is the major Cd 2+-binding component of plasma, an appreciable amount of Cd2+ may be bound to albumin.

Removal of thallium by combining desferrioxamine and deferiprone chelators in rats

The hypothesis that two known chelators deferiprone (1,2-dimethy1-3-hydroxypyrid-4-one, L1) and desferrioxamine (DFO) might be more efficient as combined treatment than as monotherapies in removing thallium from the body was tested in rats. Six-week-old male Wistar rats received chelators: L1 (p.o.), DFO (i.p.) or L1 + DFO as 110 or 220 mg/kg dose half an hour after a single i.p. administration of 8 mg Tl/kg body weight in the form of chloride. Serum thallium concentration, urinary thallium and iron excretions were determined by graphite furnace atomic absorption spectrometry. Both chelators were effective only at the higher dose level, while DFO was more effective than L1 in enhancing urinary thallium excretion, L1 was more effective than DFO in enhancing urinary iron excretion. In the combined treatment group, L1 did not increase the DFO effect on thallium and DFO did not increase the effect of L1 on iron elimination. Our results support the usefulness of this animal model for preliminary in vivo testing of thallium chelators. Urinary values were more useful because of the high variability of serum results. Result of combined chelators treatment should be confirmed in a different experimental model before extrapolation to other systems.

Aluminium transport in blood serum. Binding of aluminium by human transferrin in the presence of human albumin and citrate

The binding of Al3+ by human serum transferrin has been investigated by u.v.-visible difference spectroscopy. In the presence of 25 mM-HCO3- at pH 7.4, the apparent association constants were found to be 1.69 x 10(12) M-1 and 5.36 x 10(11) M-1. These association constants are pH-dependent, reducing with both increasing and decreasing pH. The apparent pKa values were found to be 6.7 and 8.2. Competitive assays of binding of Al3+ to transferrin in the presence of citrate and human serum albumin at molar ratios corresponding to those found in normal plasma showed that a considerable amount of Al3+ was not bound to transferrin. Taking a concentration of 5 microM as a typical value observed for the plasma of patients on haemodialysis [Harris & Sheldon (1990) Inorg. Chem. 29, 119-124] the competitive binding assay indicate that approximately 60% of it is bound to transferrin, approximately 34% to albumin and the remainder to citrate. These results therefore suggest that, although transferrin at pH 7.4 is the major Al(3+)-binding component of plasma, an appreciable amount of Al3+ present in patients on haemodialysis may be bound to albumin.

Electron transfer between horse ferritin and ferrihaemoproteins

Reactions of reduced horse spleen ferritin with horse and Saccharomyces cerevisiae ferricytochromes c, cow ferricytochrome b5, sperm-whale metmyoglobin and Pseudomonas aeruginosa ferricytochrome c-551 were investigated by u.v.-visible spectrophotometry. In all cases the reduced ferritin reduced the ferrihaemoproteins. The rate of reduction varied from less than 0.2 M-1.s-1 for metmyoglobin to 1.1 x 10(3) M-1.s-1 for horse ferricytochrome c (0.1 M-phosphate buffer, pH 7.4, at 25 degrees C). We conclude that the mechanism of ferrihaemoprotein reduction involves long-range electron transfer through the coat of ferritin and that such electron transfer is rapid enough to account for the rates of iron release observed by other workers in reductive release assays.

The effect of tea on iron and aluminium metabolism in the rat

Weanling male Wistar rats were fed for 28 d on a semi-synthetic diet containing normal (38 micrograms/g) or low (9 micrograms/g) levels of iron. They were given water or tea infusion (20 g leaves/l water) to drink. Two further groups were given a normal- or low-Fe diet containing added tea leaves (20 g/kg diet). At the end of the study period, all rats given the low-Fe diet were severely anaemic, as assessed by haemoglobin, packed cell volume and liver Fe. Those given tea or the diet with added tea leaves showed a greater degree of Fe depletion. The blood and liver aluminium levels were not increased as a result of consuming tea or tea leaves, despite the higher Al intakes. Fe deficiency per se had no effect on Al absorption or retention from tea. It was concluded that the Al in tea was very poorly absorbed but that tea, either in the form of an infusion or as tea leaves, had an adverse effect on Fe status.